efectos secundarios del tirzepatide Tirzepatida Cáncer: Evidencia y Precauciones Cuánto Tiempo Dura el Efecto

[PubMed] [Google Scholar] 196.Halliwell B

These numbers matter, because the goal is to reduce body fat while protecting muscle, not simply to drop a number on the scale

Pemvidutide, developed by Altimmune, is a GLP-1/glucagon dual agonist that has completed Phase 2 trials for obesity (MOMENTUM, 15.6% weight loss at 48 weeks) and MASH (IMPACT, up to 59.1% MASH resolution)

A minor part of the current results has been published previously [8]

Surg Obes Relat Dis 21:689694 Abi Mosleh K, Salameh Y, Ghusn W et al (2024) Impact of metabolic and bariatric surgery on weight loss and insulin requirements in type 1 and insulin-treated type 2 diabetes

References Healthline